This past May, after the last of the cases from the first wave of litigation in this campaign had been dismissed, Serenitiva LLC (an affiliate of IP Edge LLC) filed a second wave. The NPE hit Freshdesk, Zendesk, and TalkDesk, accusing each of infringing a single patent, generally related to call tracking and resolution management, through provision of their Customer Relationship Management (CRM) systems. Serenitiva also sued, in separate complaints, six customers of those companies. Now that all nine of those May cases have been dismissed, the NPE has again filed a new wave, this time against Mitel Networks (6:17-cv-00461), SAP (6:17-cv-00460), and Vocalcom (6:17-cv-00463), targeting the contact center software of each.
Following swift dismissals of all of its 2016 cases, Serenitiva LLC (an affiliate of IP Edge LLC) has filed a third wave of litigation in its Customer Relationship Management (CRM) systems campaign. The NPE has filed four separate suits against 3M Company, Bridgestone, Edmunds, and Lonely Planet over their use of the CRM systems of either Freshdesk or Zendesk, which have also been sued independently. The defendants are accused of infringing a single patent generally related to call tracking and resolution management (6,865,268).
Serenitiva LLC, a recently formed affiliate of patent monetization firm IP Edge LLC, has kicked off a litigation campaign, filing suit asserting a single patent (6,865,268) generally related to call tracking and resolution management. Three of the seven new complaints directly target the Customer Relationship Management (CRM) systems of 8×8 (6:16-cv-01290), Salesforce.com (6:16-cv-01295), and SolarWinds (6:16-cv-01288), while the other four hit companies that use those systems: American Express (6:16-cv-01296) and Koninklijke Philips (Philips Electronics) (6:16-cv-01297) for their use of Salesforce Service Cloud; Disney (6:16-cv-01289) for its use of Solarwinds web help desk, and WMPH (d/b/a iCruise.com) (6:16-cv-01291) for its use of 8×8’s Virtual Contact Center Agent Console. Serenitiva is not the first plaintiff to assert the ‘268 patent in litigation.